UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.321

Sortiert nach

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

The New England journal of medicine, 2020-11, Vol.383 (21), p.2018-2029

2020

Volltextzugriff (PDF)

Therapeutic Potential of Canakinumab Targeting the Inflammatory Cytokine Interleukin-1β for Non-small-cell Lung Cancer

Haigan, 2022/04/20, Vol.62(2), pp.81-89

Goto, Yasushi

2022

Volltextzugriff (PDF)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Scientific reports, 2021-09, Vol.11 (1), p.18762-18762, Article 18762

2021

Volltextzugriff (PDF)

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

International journal of clinical oncology, 2019-07, Vol.24 (7), p.731-770

2019

Volltextzugriff (PDF)

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1114-1122

2021

Volltextzugriff (PDF)

Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers

Cancer science, 2021-10, Vol.112 (10), p.4393-4403

2021

Volltextzugriff (PDF)

Loss of YAP1 defines neuroendocrine differentiation of lung tumors

Cancer science, 2016-10, Vol.107 (10), p.1527-1538

2016

Volltextzugriff (PDF)

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-10, Vol.124, p.179-188

2018

Volltextzugriff (PDF)

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2078-2090

2021

Volltextzugriff (PDF)

Insulinoma-associated-1 (INSM1) expression in thymic squamous cell carcinoma

Virchows Archiv : an international journal of pathology, 2022-12, Vol.481 (6), p.893-901

2022

Volltextzugriff (PDF)

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Cancer Immunology, Immunotherapy, 2020-01, Vol.69 (1), p.15-22

2020

Volltextzugriff (PDF)

Epithelioid hemangioendothelioma of the lung: CT findings and clinical course of 35 cases

Japanese journal of clinical oncology, 2020-10, Vol.50 (10), p.1195-1200

2020

Volltextzugriff (PDF)

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.387-398

2022

Volltextzugriff (PDF)

A mimic of lung adenocarcinoma: a case report of histological conversion of metastatic thyroid papillary carcinoma

Histopathology, 2022-05, Vol.80 (6), p.1004-1007

2022

Volltextzugriff (PDF)

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor

Clinical lung cancer, 2022-07, Vol.23 (5), p.386-392

2022

Volltextzugriff (PDF)

First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data

PloS one, 2021-09, Vol.16 (9), p.e0257489-e0257489

2021

Volltextzugriff (PDF)

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor

PloS one, 2018-09, Vol.13 (9), p.e0203625-e0203625

2018

Volltextzugriff (PDF)

Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single‐cell level

Cancer science, 2021-05, Vol.112 (5), p.2006-2019

2021

Volltextzugriff (PDF)

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Lung cancer (Amsterdam, Netherlands), 2016-09, Vol.99, p.4-10

2016

Volltextzugriff (PDF)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Journal of cancer research and clinical oncology, 2021, Vol.147 (1), p.245-251

2021

Volltextzugriff (PDF)

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients

Anticancer research, 2021-11, Vol.41 (11), p.5739-5747

2021

Volltextzugriff (PDF)

肺がんの医療経済

肺癌, 2023/08/20, Vol.63(4), pp.275-279

後藤, 悌

2023

Volltextzugriff (PDF)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

Cancer Immunology, Immunotherapy, 2022-03, Vol.71 (3), p.737-746

2022

Volltextzugriff (PDF)

Tumor Mutation Burden: Is It Ready for the Clinic?

Journal of clinical oncology, 2018-10, Vol.36 (30), p.2978-2979

Goto, Yasushi

2018

Volltextzugriff (PDF)

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-12, Vol.174, p.146-156

2022

Volltextzugriff (PDF)

1 – 25 von 1.321

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.067)
Mit Volltextzugriff
(1.237)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(21)

Menü

Weitere Dienste

Einstellungen

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Therapeutic Potential of Canakinumab Targeting the Inflammatory Cytokine Interleukin-1β for Non-small-cell Lung Cancer

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers

Loss of YAP1 defines neuroendocrine differentiation of lung tumors

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Insulinoma-associated-1 (INSM1) expression in thymic squamous cell carcinoma

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Epithelioid hemangioendothelioma of the lung: CT findings and clinical course of 35 cases

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

A mimic of lung adenocarcinoma: a case report of histological conversion of metastatic thyroid papillary carcinoma

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor

First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor

Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single‐cell level

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients

肺がんの医療経済

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

Tumor Mutation Burden: Is It Ready for the Clinic?

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Suchergebnisse filtern